My first spring catalog has come. The excitement at our house is at a winter high — thinking of all of the green that comes with spring and the opportunities to add to my landscape. I have marked ...

AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals’ asthma med, forcing the biotech to begin charting a new corporate course and lay off 70% of its staff in the process. The ...

Deal could be worth over $290 million if all milestones are met for each of two targets. Pieris and Daiichi Sankyo signed a a collaboration and license agreement under which Pieris will use its ...

BOSTON, MA--(Marketwired - May 10, 2017) - Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...

FREISING-WEIHENSTEPHAN, Germany, January 4 /PRNewswire/ -- Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim ...

Shares of the clinical-stage biotech company Pieris Pharmaceuticals Inc (NASDAQ: PIRS) are poised to outperform over the coming 12 to 18 months, according to William Blair. The Analyst William Blair ...

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strategic options”. AZ bought into ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities & ...

The signing of a lucrative collaboration deal causes the share price to jump. This deal provides Pieris with an up-front payment of $30 million and the ability to earn up to $1.2 billion in milestone ...

Pieris Pharmaceuticals Inc PIRS announced that partner AstraZeneca plc AZN decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4 receptor alpha ...

Phylogenetic relationships within the genus Pieris (Ericaceae) were investigated based on the rbcL and matK genes along with five spacer sequences of chloroplast DNA to address questions regarding the ...